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Myotonic dystrophy (DM) is caused by either an untranslated CTG expansion in the 3′ untranslated region of the
DMPK gene on chromosome 19 (dystrophia myotonica type 1 [DM1]), or an untranslated CCTG tetranucleotide
repeat expansion in intron 1 of the ZNF9 gene on chromosome 3 (dystrophia myotonica type 2 [DM2]). RNA-
binding proteins adhere to transcripts of the repeat expansions that accumulate in the nucleus, and a trans-dominant
dysregulation of pre-mRNA alternative splicing has been demonstrated for several genes. In muscle from patients
with DM1, altered insulin-receptor splicing to the nonmuscle isoform corresponds to the insulin insensitivity and
diabetes that are part of the DM phenotype; because of insulin-receptor species differences, this effect is not seen in
mouse models of the disease. We now demonstrate that comparable splicing abnormalities occur in DM2 muscle
prior to the development of muscle histopathology, thus demonstrating an early pathogenic effect of RNA expansions.
Myotonic dystrophy type 1 (DM1 [MIM 160900]) and
myotonic dystrophy type 2 (DM2 [MIM 602668]) are
complex multisystemic disorders with a constellation of
unusual and seemingly unrelated clinical features, in-
cluding myotonia (inability of muscle to relax), muscular
dystrophy with characteristic histological features, dis-
tinctive iridescent cataracts, cardiac conduction defects,
and various endocrine abnormalities, including insulin in-
sensitivity and testicular failure (Harper 2001; Day et al.
2003). DM1 is caused by an expanded CTG trinucleo-
tide repeat in the 3′ UTR of the dystrophia myotonica-
protein kinase (DMPK) gene (Brook et al. 1992); DM2
is caused by a CCTG tetranucleotide expansion within
intron 1 of the zinc ﬁnger protein 9 (ZNF9) gene (Liq-
uori et al. 2001). In DM1, RNA containing the CUG
expansion accumulates in ribonuclear foci and has been
associated with dysregulation of RNA-binding proteins
that have been proposed to result in a novel pathogenic
mechanism via a trans-dominant effect on pre-mRNA
alternative splicing (Philips et al. 1998; Savkur et al. 2001;
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Charlet et al. 2002; Mankodi et al. 2002; Kanadia et
al. 2003). This mechanism underlies misregulated splic-
ing of the insulin receptor (IR) and the muscle-speciﬁc
chloride-channel pre-mRNAs in DM1, leading to insulin
insensitivity and myotonia (Savkur et al. 2001; Charlet
et al. 2002; Mankodi et al. 2002). Our discovery—that
a transcribed but untranslated CCTG expansion causes
DM2 and that, similar to DM1, CCUG repeat–contain-
ing RNA accumulates in ribonuclear inclusions of af-
fected DM2 tissues—strongly suggests that pathogenic
effects of RNA cause the clinical features common to
both diseases (Liquori et al. 2001; Ranum andDay 2002).
To further investigate myotonic dystrophy (DM) patho-
genesis, we have now investigated alternative splicing in
DM2.
Alternative splicing of the IR transcripts generates two
isoforms: isoform A (IR-A), which lacks exon 11, and
isoform B (IR-B), which includes exon 11 (Seino and
Bell 1989). Normally, IR-B predominates in insulin-re-
sponsive tissues such as skeletal muscle, liver, and adi-
pose tissue. IR-B has greater insulin responsiveness than
does IR-A (Moller et al. 1989). A consistent ﬁnding in
individuals with DM1 is expression of the nonmuscle
IR-A isoform in skeletal-muscle tissue and primary-mus-
cle cultures (Furling et al. 2001; Savkur et al. 2001). To
investigate the role of misregulated alternative splicing
in DM2 pathogenesis, we investigated IR splicing in
muscle from subjects with DM2.
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Table 1
Comparison of Glucose Tolerance, Muscle Histology, and IR Isoform Expression for Subjects with DM2, Subjects with DM1,
and Normal Subjects
Subject Sex
Age at Biopsy
(years)
Fasting Glucosea
(mg/dl)
Fasting Insulinb
(mU/liter)
2-h Glucosec
(mg/dl) HOMA Ratiod Bx Score
IR-B
(%)
DM2 1 M 52 107 9 135 2.4 5 12
DM2 2 M 35 94 22 187 5.1 4 18
DM2 3 M 33 95 13 109 3.1 3 20
DM2 4 M 66 89 16 165 3.5 6 23
DM2 5 M 43 86 4 23
DM2 6 M 64 84 20 132 4.2 6 26
DM2 7a F 26 0 26
DM2 7b F 34 96 23 90 5.5 6 4
DM2 8 M 35 93 8 114 1.9 3
DM2 9 M 55 98 9 93 2.2 6
DM2 10 M 42 89 11 121 2.4 7
DM2 11 M 52 176 13 279 5.7 7
DM2 12 F 65 229 18 379 10.3 4
DM2 13 F 62 102 67 153 17.0 4
MeanSD 4714 11143 1916 16385 5.34.4 52 198
DM1 A M 46 75 6 10
DM1 B F 59 86 1 35
DM1 C M 30 102 0 41
MeanSD 4515 8814 23 2916
Normal A F 48 83 3 123 .6 0 60
Normal B F 70 87 3 118 .6 0
Normal C F 37 88 6 112 1.3 0
MeanSD 5217 863 42 1186 .8.4 00
NOTE.—For DM2 versus DM1: age at biopsy ; fasting-glucose level ; Bx Score ; IR-B% . For DM2Pp .84 Pp .24 Pp .43 Pp .42
versus for normal subjects: age at biopsy ; fasting-glucose level ; fasting-insulin level ; 2-h glucose levelPp .71 Pp .06 Pp .008 Pp
; HOMA Ratio ; Bx Score ..09 Pp .005 Pp .000
a Expected fasting glucose levels: normal (Nl) !110 mg/dl; impaired glucose tolerance (IGT) 110–126 mg/dl; non–insulin-dependent
diabetes mellitus (NIDDM) 1126 mg/dl.
b Expected fasting insulin levels: Nl !20 mU/liter; IGT 20 mU/liter.
c Expected 2-h glucose levels: Nl !140 mg/dl; IGT 140–200 mg/dl; NIDDM 1200 mg/dl.
d Expected HOMA ratio: Nl 0–3.2; IGT 3.3–6.8; NIDDM 16.8.
Subjects with DM2were enrolled from theMN1 fami-
ly in which the DM2 locus was initially mapped (Ranum
et al. 1998). All patients had the cardinal features ofDM2:
muscle weakness (often restricted to neck ﬂexors, deep-
ﬁnger ﬂexors, or hip extensors), electrical myotonia, mus-
cular dystrophy, and cataracts. All muscle biopsies were
performed on the vastus lateralis, except for a single
diagnostic biceps brachii biopsy done of a subject who,
8 years later, also had a research biopsy of the vastus
lateralis. Glucose-tolerance testing was performed fol-
lowing a 12-h fast, with measurement of the glucose and
insulin levels before and at .5-h intervals after ingestion
of 200 g of glucose.Measurements of glucose intolerance
included fasting glucose, fasting insulin (Laakso 1993),
glucose measurement 2 h after glucose ingestion, and the
homeostasis model assessment (HOMA) ratio (Matthews
et al. 1985). Results for subjects with DM2 were com-
pared with results in normal subjects; subjects withDM1
underwent biopsies but were not recruited for the glu-
cose-tolerance test. All studies were done under approval
of the University of Minnesota institutional review board
for human research.
DNA from blood cells was used to verify the presence
of a DM2 expansion, as reported elsewhere (Day et al.
2003). Muscle specimens for both biochemical and histo-
logical analyses were quick-frozen in methyl butane that
was suspended in liquid nitrogen. Routine histology on
frozen sections of muscles was graded for each of four
features (ﬁbrosis, necrosis, central nuclei proliferation,
and presence of pyknotic nuclear clump ﬁbers), grading
each feature as absent (0), moderately present (1), or
diffusely present (2); the sum of scores for all four fea-
tures is reported in table 1 as the biopsy score (Bx Score)
(0–8, 8 being maximally abnormal). To verify that ex-
panded CCUG transcripts accumulate as ribonuclear in-
clusions, muscle biopsies were also evaluated, by RNA-
FISH, as described elsewhere (Liquori et al. 2001). RNA
was extracted from muscle, and the percentage of IR
mRNAs containing exon 11 was determined by RT-PCR
(ﬁg. 1), as described elsewhere (Savkur et al. 2001). IR
RT-PCR results are expressed in tables 1 and 2 as per-
centage of IR-B, which was calculated from the RT-PCR
results: .[CPM IR-B/(CPM IR-A CPM IR-B)]# 100
Mean and SEs are given for the different subject groups,
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Table 2
Comparison of IR Isoform Expression
in Subjects with DM1, Subjects with DM2,
and Normal Subjects
Subjects
Percentage of Insulin-
Sensitive IR-B
(MeanSD)
Unaffected ( )np 9 667
With DM1 ( )np 4 2912
With DM2 ( )np 8 198
Figure 1 Measurement of IR isoforms: RT-PCR analyses of IR isoforms in RNA from DM1, DM2, and normal muscle biopsies. The
upper band represents the insulin-sensitive IR-B isoform (containing exon 11), and the lower band shows the insulin-insensitive IR-A isoform
(without exon 11). In DM1 and DM2 muscle, the IR-A isoform predominates, as evidenced by the low percentage of IR-B relative to that in
unaffected control.
and P values are given, as determined by Student’s t test
comparisons between DM2 and DM1 and between DM2
and normal muscle. Reference ranges shown in the table
deﬁne the various glucose and insulin measurements for
normal subjects, subjects with impaired glucose toler-
ance, and subjects with non–insulin-dependent diabetes
mellitus.
Of the 13 subjects with DM2 who were tested for glu-
cose intolerance, 7 showed some degree of insulin in-
sensitivity (table 1). The most sensitive indicator of in-
sulin insensitivity, the HOMA ratio, was abnormal in
seven subjects. Two subjects had abnormal fasting glu-
cose levels, and ﬁve had abnormal glucose levels 2 h after
glucose administration (table 1). As indicated in table 1,
fasting insulin levels and the HOMA ratio signiﬁcantly
( ) differed between subjects with DM2 and nor-P ! .01
mal subjects, with a trend in subjects with DM2 toward
abnormal fasting glucose and 2-h glucose determinations
during the glucose-tolerance test.
Biopsy results of 13 subjects were analyzed. One sub-
ject (DM2 7) (table 1) had two biopsies 8 years apart;
results of her ﬁrst biopsy (DM2 7a), obtained from the
biceps brachii at the time of initial diagnosis at age 26
years, were histologically normal, but the second (DM2
7b), from the vastus lateralis at age 34 years, had histo-
logical changes typical of DM2. All other biopsy results
from patients with DM2 showed the typical pathology
of DM, including atrophic angulated ﬁbers, severely
atrophic ﬁbers with pyknotic nuclei, and proliferation
of centrally located nuclei. When examined by RNA-
FISH, all muscle specimens, including the histologically
normal 1993 biopsy from individual 7 (specimen DM2
7a), had ribonuclear inclusions detectable by FISH (ﬁg.
2). The detection of ribonuclear inclusions in sample 7a
before development of pathological changes indicates
that the ribonuclear inclusions occur before histopa-
thology rather than being an indirect consequence of the
dystrophic changes.
The percentage of IR-A and IR-B isoforms of the IR in
skeletal muscle from subjects with DM1, subjects with
DM2, and control individualswas determinedbyRT-PCR
by use of 32P-labeled forward PCR oligo, as described
elsewhere (Savkur et al. 2001). The percentage of the IR-
B splice form was reduced in all DM2 specimens, com-
pared with specimens from normal control individuals
(ﬁg. 1; table 2). The percentage of IR-B in normal control
individuals (table 2) differed signiﬁcantly from that in
DM2 muscle (normal range 60%–80%, mean 667%;
DM2 range 8%–40%, mean 198%; ). Muscle8P ! 10
biopsy 7a, which had normal histology (Bx score 0) (table
1) but did contain ribonuclear inclusions, had a clearly
abnormal percentage of IR-B (26%) (table 1). The sample
from this same individual 8 years later showed abnormal
histology (Bx score 6) (table 1) and only 4% IR-B (table
1). These results demonstrate that IR splicing abnormali-
ties and ribonuclear inclusions both precede development
of dystrophic changes.
Our results demonstrate that IR splicing is altered in
DM2; exon 11 inclusion is signiﬁcantly lower in muscle
from subjects with DM2 than in normal subjects. Similar
results have been reported elsewhere in developing mus-
cle and in adult skeletal muscle from subjects with DM1
(Savkur et al. 2001). This splice change results in reduced
expression of insulin-sensitive receptors in skeletal mus-
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Figure 2 Histological and FISH features in DM2: histological sections of skeletal-muscle biopsies on the same patient, performed 8 years
apart. The earlier biopsy from biceps brachii (A1 and B1) shows normal histology, with only one ﬁber in the entire section having a single
central nucleus (arrowhead). The later biopsy from vastus lateralis (A2 and B2) shows characteristic histological features of DM, with angulated
ﬁbers, severely atrophic ﬁbers with pyknotic nuclei (“nuclear bag ﬁbers”) (indicated by an asterisk [*]), and proliferation of centrally located
nuclei (arrowhead). RNA-FISH shows ribonuclear inclusions (red foci, small arrows) within blue DAPI-stained nuclei in both samples (B1 and
B2), including within all nuclei of a severely atrophic ﬁber (inset).
cle and corresponds to clinical observation of insulin in-
sensitivity and diabetes in DM1 and DM2. The degree
of IR-splicing change in DM2 (mean 25% IR-B) is com-
parable to the change found in DM1 (mean 38% IR-
B), although other variables—such as age, muscle histo-
pathology, or obesity—may also affect the ratio. The role
of altered IR splicing has not been evaluated in typical
patients with type 2 diabetes mellitus who do not have
muscular dystrophy, in whom insulin insensitivity can
result from other changes in receptor function. We have
shown elsewhere that muscle specimens from subjects
with other forms of muscular dystrophy and other neu-
romuscular disorders do not have abnormal IR splicing
(Savkur et al. 2001). The data reported here of IR splic-
ing in DM2, taken together with other evidence of al-
tered gene splicing in DM1 andDM2 (Philips et al. 1998;
Savkur et al. 2001; Charlet et al. 2002; Mankodi et al.
2002; Kanadia et al. 2003), support the model that al-
teredRNAprocessing underliesDMpathogenesis, though
additional functionally signiﬁcant changes in IR could
also occur.
Evaluation of the histologically normal DM2 muscle
biopsy shows that pathogenic splicing alterations occur
prior to development of dystrophic changes, verifying
that aberrant RNA processing is an early feature of DM
rather than being secondary tomuscle-ﬁber degeneration
or regeneration. Ribonuclear inclusions were present in
the histologically normal specimen, as they were in all
histologically abnormal specimens. The role of these in-
clusions in disease pathogenesis remains unclear, but in-
clusions and splicing changes are clearly present prior
to the development of muscle degeneration. Finding that
splicing changes precede histological abnormalities sup-
ports the view that splicing abnormalities are a primary
event of the disease rather than being secondary to ex-
pansion of the satellite cell population during regenera-
tion. Overt regeneration was not observed in these speci-
mens that showed splicing changes, consistent with
studies on DM1 tissues that showed the splicing switch
in tissues in which markers of skeletal-muscle regenera-
tion were not elevated (Savkur et al. 2001). Our ﬁnding
that IR splicing changes in DM2 are an early molecular
change in the disease is consistent with the observation
that insulin resistance is an early manifestation of DM1
(Moxley et al. 1978, 1980).
Although abnormal chloride-channel splicing has been
demonstrated in muscle both from patients with DM and
from transgenic mice that carry a pathogenic CTG ex-
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pansion, IR splicing can be investigated only in humans,
because mouse skeletal muscle does not regulate IR splic-
ing in the same way that human muscle does (Kanadia
et al. 2003). Consequently, our identiﬁcation of abnor-
mal alternative IR splicing in skeletal muscle from sub-
jects with DM2 and DM1 veriﬁes the importance of this
mechanism in development of clinical insulin insensitiv-
ity in a way that cannot be studied in the mouse models.
The fact that DM2 and DM1 result in similar IR-splicing
abnormalities provides additional evidence that these ge-
netically distinct disorders share a common molecular
mechanism. Since the genes at the DM1 and DM2 loci
have no evident functional ormechanistic similarities, and
because both disorders are caused by untranslated mi-
crosatellite expansions, the most likely explanation is that
the multisystemic features of both disorders result from
the deleterious effects of RNA transcripts containingCUG
or CCUG repeat expansions.
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